Drug Interactions between azathioprine and Plaquenil
This report displays the potential drug interactions for the following 2 drugs:
- azathioprine
- Plaquenil (hydroxychloroquine)
Interactions between your drugs
No interactions were found between azathioprine and Plaquenil. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
azathioprine
A total of 436 drugs are known to interact with azathioprine.
- Azathioprine is in the following drug classes: antirheumatics, other immunosuppressants.
-
Azathioprine is used to treat the following conditions:
- Atopic Dermatitis
- Autoimmune Hepatitis
- Behcet's Disease (off-label)
- Bullous Pemphigoid (off-label)
- Chronic Active Hepatitis
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Cogan's Syndrome (off-label)
- Crohn's Disease
- Crohn's Disease, Active
- Crohn's Disease, Maintenance
- Dermatomyositis (off-label)
- Eczema (off-label)
- Glomerulonephritis (off-label)
- Granulomatosis with Polyangiitis
- Immune Thrombocytopenia (off-label)
- Immunoglobulin G4-Related Disease (off-label)
- Inflammatory Bowel Disease
- Lupus
- Lupus Nephritis (off-label)
- Multiple Sclerosis
- Myasthenia Gravis (off-label)
- Myopathy (off-label)
- Nephrotic Syndrome (off-label)
- Neurosarcoidosis (off-label)
- Organ Transplant, Rejection Prophylaxis
- Pemphigoid (off-label)
- Pemphigus (off-label)
- Primary Biliary Cholangitis (off-label)
- Psoriatic Arthritis (off-label)
- Renal Transplant
- Rheumatoid Arthritis
- Sarcoidosis
- Takayasu's Arteritis
- Ulcerative Colitis
- Uveitis
Plaquenil
A total of 582 drugs are known to interact with Plaquenil.
- Plaquenil is in the following drug classes: antimalarial quinolines, antirheumatics.
- Plaquenil is used to treat the following conditions:
Drug and food interactions
hydroxychloroquine food
Applies to: Plaquenil (hydroxychloroquine)
GENERALLY AVOID: Theoretically, grapefruit and grapefruit juice may increase the plasma concentrations of hydroxychloroquine or chloroquine and the risk of toxicities such as QT interval prolongation and ventricular arrhythmias. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruit. Following coadministration with cimetidine, a weak to moderate CYP450 3A4 inhibitor, a 2-fold increase in chloroquine exposure occurred. Since chloroquine and hydroxychloroquine have similar structures and metabolic elimination pathways, a similar interaction may be observed with hydroxychloroquine. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Pharmacokinetic interactions involving grapefruit juice are also subject to a high degree of interpatient variability, thus the extent to which a given patient may be affected is difficult to predict.
ADJUST DOSING INTERVAL: Administration with food or milk may reduce the incidence of hydroxychloroquine-related gastrointestinal adverse effects.
MANAGEMENT: Although clinical data are lacking, it may be advisable to avoid the consumption of grapefruit, grapefruit juice, and any supplement containing grapefruit extract during hydroxychloroquine or chloroquine therapy. Hydroxychloroquine should be administered with food or milk to reduce the occurrence of gastrointestinal upset.
References (5)
- (2024) "Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine)." Dr. Reddy's Laboratories Inc
- (2023) "Product Information. Plaquenil (hydroxychloroquine)." Sanofi-Aventis Canada Inc
- (2024) "Product Information. Quinoric (hydroxychloroquine)." Bristol Laboratories Ltd
- (2024) "Product Information. Hydroxychloroquine (GH) (hydroxychloroquine)." Generic Health Pty Ltd
- (2023) "Product Information. HIDROXICLOROQUINA RATIOPHARM (hidroxicloroquina)." RATIOPHARM ESPANA S.A.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.